Muhammad W Saif

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. ncbi request reprint Medullary carcinoma of the colon: a case series and review of the literature
    Julia Cunningham
    MBBS, Director, Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, 800 Washington Street, Boston, MA 02111, U S A
    In Vivo 28:311-4. 2014
  2. ncbi request reprint Gastrointestinal stromal tumor of colon: a case report and review of literature
    Azfar Khan Niazi
    MBBS, Director, Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine and Tufts Cancer Center, 800 Washington Street, Boston, MA 02111, U S A
    Anticancer Res 34:2547-50. 2014
  3. pmc Desmoplasia in pancreatic cancer. Can we fight it?
    E E Merika
    Oncology Unit, Third Department of Medicine, Sotiria General Hospital, University of Athens, 10679 Athens, Greece
    Gastroenterol Res Pract 2012:781765. 2012
  4. pmc Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
    Muhammad Wasif Saif
    GI Oncology Program, Tufts University School of Medicine, Boston, MA, USA
    Cancer Manag Res 5:103-15. 2013
  5. ncbi request reprint First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, 800 Washington Street, Boston, MA, 02111, USA
    Cancer Chemother Pharmacol 73:373-80. 2014
  6. ncbi request reprint Gemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 15:38-41. 2014
  7. ncbi request reprint A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach
    Muhammad Wasif Saif
    Division of Hematology Oncology and Experimental Therapeutics, Tufts Medical Center, Boston, MA Electronic address
    Mayo Clin Proc 89:131-6. 2014
  8. ncbi request reprint Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer
    Sun Young Oh
    Department of Hematology Oncology and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 14:676-9. 2013
  9. ncbi request reprint Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different
    Muhammad Wasif Saif
    Experimental Therapeutics Program, Tufts University School of Medicine, 800 Washington Street, Suite 7S 7099, Boston, MA 02111, USA 1 617 636 8077 1 617 636 7060
    Expert Opin Biol Ther 13:1489-93. 2013
  10. ncbi request reprint Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production: a case report and review of literature
    Forum B Patel
    Department of Medicine and Cancer Center, Tufts Medical Center, 800 Washington Street Box 245, Boston, MA 02111, U S A
    Anticancer Res 33:4001-5. 2013

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Medullary carcinoma of the colon: a case series and review of the literature
    Julia Cunningham
    MBBS, Director, Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, 800 Washington Street, Boston, MA 02111, U S A
    In Vivo 28:311-4. 2014
    ..Only a handful of studies have been conducted thus far, mostly focusing on immunohistochemical and clinical characteristics of the disease...
  2. ncbi request reprint Gastrointestinal stromal tumor of colon: a case report and review of literature
    Azfar Khan Niazi
    MBBS, Director, Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine and Tufts Cancer Center, 800 Washington Street, Boston, MA 02111, U S A
    Anticancer Res 34:2547-50. 2014
    ..Case Report: We report on a case with GIST in the colon treated with surgical resection followed by adjuvant imatinib therapy. This treatment showed no side-effects, and subsequent colonoscopy was unremarkable...
  3. pmc Desmoplasia in pancreatic cancer. Can we fight it?
    E E Merika
    Oncology Unit, Third Department of Medicine, Sotiria General Hospital, University of Athens, 10679 Athens, Greece
    Gastroenterol Res Pract 2012:781765. 2012
    ....
  4. pmc Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
    Muhammad Wasif Saif
    GI Oncology Program, Tufts University School of Medicine, Boston, MA, USA
    Cancer Manag Res 5:103-15. 2013
    ..Newer antiangiogenesis therapies should help further expand treatment options for colorectal and other cancers. Comparative preclinical data on these agents is currently lacking. ..
  5. ncbi request reprint First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, 800 Washington Street, Boston, MA, 02111, USA
    Cancer Chemother Pharmacol 73:373-80. 2014
    ..We conducted this phase II study to explore the efficacy of capecitabine and PHY906 in patients with advanced pancreatic cancer who were previously treated with gemcitabine-based regimens...
  6. ncbi request reprint Gemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 15:38-41. 2014
    ..The combination of etoposide and cisplatin is considered as the first-line treatment, but no recommendations exist for further treatment after progression...
  7. ncbi request reprint A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach
    Muhammad Wasif Saif
    Division of Hematology Oncology and Experimental Therapeutics, Tufts Medical Center, Boston, MA Electronic address
    Mayo Clin Proc 89:131-6. 2014
    ..This case suggests that Y186C may have contributed to 5-FU toxicity in this patient and supports the use of Y186C as a predictive marker for 5-FU toxic effects in individuals of African ancestry. ..
  8. ncbi request reprint Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer
    Sun Young Oh
    Department of Hematology Oncology and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 14:676-9. 2013
    ..Neurotoxicity is the dose limiting toxicity and ototoxicity is very rare, less than 1% of patients...
  9. ncbi request reprint Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different
    Muhammad Wasif Saif
    Experimental Therapeutics Program, Tufts University School of Medicine, 800 Washington Street, Suite 7S 7099, Boston, MA 02111, USA 1 617 636 8077 1 617 636 7060
    Expert Opin Biol Ther 13:1489-93. 2013
    ..The author comments on this issue and emphasizes the need for additional research into antiangiogenic biomarkers to identify patients who are likely to respond to one drug more than another. ..
  10. ncbi request reprint Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production: a case report and review of literature
    Forum B Patel
    Department of Medicine and Cancer Center, Tufts Medical Center, 800 Washington Street Box 245, Boston, MA 02111, U S A
    Anticancer Res 33:4001-5. 2013
    ..Although resection of the pancreatic mass was performed, the patient presented again with metastatic disease to the liver. ..
  11. doi request reprint A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 14:498-501. 2013
    ..Pancreatic neuroendocrine tumors (pNETs) are notoriously resistant to currently available chemotherapy agents. Preclinical data has suggested synergy between temozolomide and capecitabine...
  12. ncbi request reprint Tumor markers in pancreatic cancer: 2013
    Urvi Ajay Shah
    Tufts Medical Center Boston, MA 02111, USA
    JOP 14:318-21. 2013
    ..We will discuss four abstracts presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which contribute to expanding the application of CA 19-9 measurement (Abstracts #4042, #4058, #e15082, #e15146). ..
  13. ncbi request reprint Utilizing endoscopic ultrasound-guided fine needle aspiration in identifying molecular targets for pancreatic cancer
    Onyekachi Henry Ogbonna
    Tufts University School of Medicine Boston, MA 02111, USA
    JOP 14:316-7. 2013
    ..We summarize their findings and discuss the possibility of utilizing this model to obtain a better understanding of pancreatic cancer at each stage of its metamorphosis and target therapy at these different levels. ..
  14. ncbi request reprint First line therapy for metastatic pancreatic cancer
    Jamie Jarboe
    Tufts Cancer Center Boston, MA, USA
    JOP 14:340-3. 2013
    ..We will discuss the results of the MPACT trial presented at the 2013 ASCO Annual Meeting (Abstracts #4005, #4058, and #4059) and compare to the 2011 FOLFIRINOX data. ..
  15. ncbi request reprint New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma
    Vasilis Stefanos Ramfidis
    University of Pittsburgh Cancer Institute Pittsburgh, PA, USA
    JOP 14:344-6. 2013
    ....
  16. ncbi request reprint Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
    Alexios S Strimpakos
    Division of Oncology, Second Department of Internal Medicine, Attikon University Hospital, Athens, Greece
    JOP 14:354-8. 2013
    ..The aforementioned early phase studies open new therapeutic approaches which deserve further testing in advanced pancreatic cancer. ..
  17. ncbi request reprint Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications
    Alexios S Strimpakos
    Division of Oncology, Second Department of Internal Medicine, Attikon University Hospital, Greece
    JOP 14:359-62. 2013
    ..Of course, there is a long way to go before implementation of these genomic findings, with the exception of hENT1 which seems to be close for clinical use. ..
  18. ncbi request reprint Diabetes and pancreatic cancer
    Najla Hatem El-Jurdi
    Tufts University School of Medicine Boston, MA 02111, USA
    JOP 14:363-6. 2013
    ....
  19. ncbi request reprint Update on novel therapies for pancreatic neuroendocrine tumors: 2013
    Anastasios Dimou
    Department of Medicine, Albert Einstein Medical Center Philadelphia, PA, USA
    JOP 14:377-80. 2013
    ..Last but not least, we discuss the updated data from a phase II study that used the combination of temsirolimus with bevacizumab in patients with advanced pNETs (Abstract #4032). ..
  20. ncbi request reprint Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    In Vivo 27:531-4. 2013
    ..The incidence of cardiotoxicity associated with 5-FU ranges from 1.5% to 18%; 48% as anginal symptoms and 2% as cardiogenic shock. Cardiotoxicity is unpredictable and no alternative chemotherapeutics have been defined so far...
  21. ncbi request reprint Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Anticancer Res 33:2743-6. 2013
    ..To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer...
  22. ncbi request reprint Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
    Muhammad Wasif Saif
    Division of Hematology Oncology, Department of Medicine, Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Anticancer Res 33:2377-80. 2013
    ..The author reviews the data on anti-VEGF therapy in metastatic colorectal cancer...
  23. ncbi request reprint Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions
    Muhammad Wasif Saif
    Tufts University School of Medicine, Division of Hematology Oncology, Department of Medicine, Director, GI Oncology Program 800 Washington Street, Box 245, Boston, MA 02111, USA
    Anticancer Res 33:2175-7. 2013
    ..We share our experience using concurrent capecitabine or infusional 5-fluorouracil with radiation for patients with resected and locally advanced PNET...
  24. doi request reprint Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors
    M W Saif
    Hematology Oncology, Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Cancer Chemother Pharmacol 71:1345-55. 2013
    ..We have undertaken a Phase 1 trial of CNF1010, an oil-in-water nanoemulsion of 17-AAG...
  25. ncbi request reprint Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD
    Muhammad Wasif Saif
    Tufts Medical Center, Tufts University School of Medicine, Division of Hematology Oncology, Department of Medicine, Director, GI Oncology Program, 800 Washington Street, Box 245, Boston, MA 02111, USA
    Cancer Genomics Proteomics 10:89-92. 2013
    ..We present the analysis of DPYD genotyping in untreated Caucasian patients (control group) and Caucasian patients with 5-FU/CAP-related grade 3/4 toxicities (toxicity group) who underwent a capecitabine TheraGuide 5-FU testing...
  26. ncbi request reprint Adenocarcinoma ex goblet cell carcinoid in a renal transplant patient: a case report and review of the literature
    M Wasif Saif
    GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Anticancer Res 33:1753-6. 2013
    ..We report on a case of a 45-year-old woman, post-renal transplant who presented with ovarian metastases from this tumor. This appears to be the first report of an adenocarcinoma ex goblet cell carcinoid in a renal transplant recipient...
  27. ncbi request reprint Small cell carcinoma of the colon arising in a carcinoid tumor
    M Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Anticancer Res 33:1713-5. 2013
    ..Although small cell carcinomas of the colon have frequently been found in association with colonic adenomas, this appears to be the first report of a low-grade carcinoid tumor in combination with a small cell carcinoma...
  28. doi request reprint Advancements in the management of pancreatic cancer: 2013
    Muhammad Wasif Saif
    Tufts Medical Center Boston, MA, USA
    JOP 14:112-8. 2013
    ..At the end of one year, 35% of those getting nab-paclitaxel were alive, compared with 22% of those getting only gemcitabine. After two years, the figures were 9% for those getting nab-paclitaxel and 4% for those who received gemcitabine...
  29. doi request reprint Thromboembolism and anticoagulation in pancreatic cancer
    Muzzamal Habib
    St Elizabeth s Medical Center, Boston, MA, USA
    JOP 14:135-7. 2013
    ..Additionally the authors review the risk of thrombosis associated with the chemotherapy and erythropoiesis stimulating agents and its prognostic implications and possible managements...
  30. doi request reprint BRCA-associated pancreatic cancer: the evolving management
    Keith Leung
    Division of Hematology Oncology, Department of Medicine and Cancer Center, Tufts Medical Center, Boston, MA 02111, USA
    JOP 14:149-51. 2013
    ..We will review these abstracts and our current knowledge of the treatment for patients with BRCA-associated pancreatic cancer. In this group of patients, these new results continue to shape our understanding of this disease...
  31. doi request reprint Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects
    Froso Konstantinou
    Oncology Unit, Third Department of Medicine, Athens School of Medicine, Sotiria General Hospital, Athens, Greece
    JOP 14:141-4. 2013
    ..Herein, the authors summarize the data presented at the 2013 ASCO Gastrointestinal Cancers Symposium regarding incidence and clinicopathological characteristics of IPMN (Abstracts #324, #187 and #179)...
  32. doi request reprint Pancreatic cancer: updates on translational research and future applications
    Evangelos G Sarris
    Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece
    JOP 14:145-8. 2013
    ..Lastly, in Abstract #164, the diagnostic utility of YKL-40 and IL-6 in pancreatic cancer patients is investigated...
  33. doi request reprint Ampullary and periampullary adenocarcinoma: new challenges in management of recurrence
    Vassilis S Ramfidis
    Oncology Unit, 251 General Hospital of Airforce, Athens, Greece
    JOP 14:158-60. 2013
    ....
  34. ncbi request reprint Gemcitabine-induced pulmonary toxicity
    Dow Chung Chi
    Tufts Medical Center, Boston, MA 02111, USA
    Anticancer Res 32:4147-9. 2012
    ..Mild to moderate emphysema was also seen, but no pulmonary emboli were detected. Myocardial infraction was ruled-out by normal electrocardiogram and normal cardiac biomarkers...
  35. doi request reprint Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma
    Alexios S Strimpakos
    Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece
    JOP 13:338-41. 2012
    ....
  36. doi request reprint Use of supportive care for symptom management in pancreatic cancer: application of clinical research to patient care
    Meropi Panagiotarakou
    Oncology Unit, Sotiria General Hospital, University of Athens, Athens, Greece
    JOP 13:342-4. 2012
    ..All of these abstracts explore innovative ways to control symptoms in cancer patients. We are hopeful that these methods are able to be used in symptomatic pancreatic cancer patients...
  37. doi request reprint New tools and novel approaches in treating locally advanced pancreatic adenocarcinoma
    Wesam B Ahmed
    Division of Hematology Oncology, Department of Radiation Oncology, Tufts Medical Center, Boston, MA 02111, USA
    JOP 13:354-7. 2012
    ..The phase II results showed a median overall survival of 15.9 months, suggesting that SBRT may be an emerging tool in the multi-modality treatment of locally advanced pancreatic cancer...
  38. doi request reprint Highlights on the first line treatment of metastatic pancreatic cancer
    Krishna S Gunturu
    Department of Medicine and Cancer Center, Tufts Medical Center, Boston, MA 02111, USA
    JOP 13:361-7. 2012
    ..The 2012 American Society of Oncology (ASCO) Annual Meeting offered new insights into metastatic pancreatic cancer and we discuss Abstracts #4018, #4019, #4022, #4042, #4043, #4048, #4050 and comment on them in this paper...
  39. doi request reprint Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
    Vassilios S Ramfidis
    Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece
    JOP 13:358-60. 2012
    ..Finally, the efficacy and toxicity of lapatinib combined with either FOLFOX (Abstract #e14533) or capecitabine (Abstract #e14569) were examined in the second line setting of pancreatic cancer...
  40. ncbi request reprint Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011
    Nektaria Makrilia
    Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School, Athens, Greece
    JOP 12:351-4. 2011
    ....
  41. doi request reprint Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer
    Alexios S Strimpakos
    Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece
    JOP 13:345-8. 2012
    ....
  42. ncbi request reprint Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol
    Ekaterini I Syrigou
    Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School, Athens, Greece
    Clin Colorectal Cancer 8:106-9. 2009
    ..Premedication and an increased infusion time could allow for readministration. The desensitization protocol we developed can provide a reliable alternative to permanent discontinuation of oxaliplatin...
  43. ncbi request reprint The need for third-line treatment in non-small cell lung cancer: an overview of new options
    Kostas N Syrigos
    Oncology Unit, Sotiria General Hospital, Athens School of Medicine, Athens, Greece
    Anticancer Res 31:649-59. 2011
    ..In an effort to prolong survival while maintaining quality of life, large prospective studies are needed to examine the effectiveness and safety of third-line regimens in these patients...
  44. doi request reprint Hypersensitivity reactions to antineoplastic agents: an overview
    Ekaterini Syrigou
    Oncology Unit, 3rd Department of Medicine, Athens School of Medicine, Sotiria General Hospital, Athens, Greece
    Anticancer Drugs 20:1-6. 2009
    ..Once hypersensitivity reactions are observed, basic principles that allow their management and possible continuance and completion of the regimen should be followed...
  45. doi request reprint Pulmonary blastoma with submandibular, scrotum and adrenal metastases: case report
    Kostas N Syrigos
    Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens University School of Medicine, Athens, Greece
    Respiration 83:83-6. 2012
    ..Treatment strategy in pulmonary blastoma should be defined by a multidisciplinary team, and surgical treatment should be considered as quickly as possible when such a tumor is suspected...
  46. doi request reprint Multimodal treatment strategies for elderly patients with head and neck cancer
    Evangelos G Sarris
    Oncology Unit GPP, Sotiria General Hospital, Athens Medical School, Building Z, 152 Mesogion Av, 115 27 Athens, Greece
    Cancer Treat Rev 40:465-75. 2014
    ..The aim of this review article is to investigate the multimodal treatment approaches for elderly patients with head and neck cancer. ..
  47. ncbi request reprint Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol
    Ekaterini I Syrigou
    Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School, Athens, Greece
    Clin Colorectal Cancer 8:106-9. 2009
    ..For these reasons, we analyzed retrospectively the records of 215 CRC patients treated with oxaliplatin-containing regimens either as an adjuvant, first-line, second-line, or more...
  48. pmc Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report
    Kostas N Syrigos
    Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece
    Ital J Pediatr 37:42. 2011
    ....
  49. doi request reprint Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy
    Elias A Kotteas
    Oncology Unit GPP, Sotiria General Hospital, Athens School of Medicine, 152, Mesogeion av, 115 27, Athens, Greece
    Med Oncol 30:662. 2013
    ..Also, a possible role for soluble ICAM-1 may exist as a predictive marker for objective response during chemotherapy for patients with extensive disease (p = 0.001). ..
  50. pmc Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma
    Muhammad W Saif
    Division of Hematology, Oncology, Department of Medicine, Columbia University, NY 10027, USA
    Gastroenterol Res Pract 2011:616080. 2011
    ..Sorafenib was discontinued in both cases. Physicians should monitor patients receiving sorafenib for neurologic symptoms, and in the absence of other etiology, prompt discontinuation of this drug should be considered...
  51. pmc The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series
    Muhammad W Saif
    Division of Hematology and Oncology, Department of Medicine, Columbia University, New York, NY 10032 3784, USA
    J Oncol 2011:125467. 2011
    ..We conclude that EGFR inhibitors may play a vital role in the treatment of anal cancer and we suggest that large trials are be conducted in order to clarify their efficacy and to improve therapeutic management...